Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for patients with EGFR-mutated non-small cell lung cancer (NSCLC) has been shown to have superior outcomes when compared to chemotherapy. First-generation EGFR TKI, including gefitinib and erlotinib, and second-generation EGFR TKI, including afatinib and dacomitinib, proved to be effective in patients with NSCLC harboring EGFR-sensitizing mutation. Later, resistance mutations were identified. Consequently, osimertinib, a third-generation EGFR TKI, was studied and demonstrated activity against EGFR-sensitizing and resistant mutations. Osimertinib moved recently to the first-line setting with the positive results of the FLAURA (AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer) trial. The use of these drugs is limited by their cost and availability mainly in middle- to low-income countries.
HerbstRSHeymachJVLippmanSM.Lung cancer. N Engl J Med2008; 359: 1367–1380.
3.
SequistLVBellDWLynchTJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol2007; 25: 587–595.
4.
SridharSSSeymourLShepherdFA.Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol2003; 4: 397–406.
5.
RabenDHelfrichBAChanD, et al. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol2002; 29 (1Suppl 4): 37–46.
6.
WakelingAEGuySPWoodburnJR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res2002; 62: 5749–5754.
7.
SirotnakFMZakowskiMFMillerVA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res2000; 6: 4885–4892.
8.
FukuokaMYanoSGiacconeG, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol2003; 21: 2237–2246.
9.
KrisMGNataleRBHerbstRS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA2003; 290: 2149–2158.
10.
MokTSWuYLThongprasertS, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med2009; 361: 947–957.
11.
FukuokaMWuYLThongprasertS, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol2011; 29: 2866–2874.
12.
MitsudomiTMoritaSYatabeY, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010; 11: 121–128.
13.
HanJYParkKKimSW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol2012; 30: 1122–1128.
14.
MaemondoMInoueAKobayashiK, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010; 362: 2380–2388.
15.
SoriaJCWuYLNakagawaK, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol2015; 16: 990–998.
16.
ShepherdFARodrigues PereiraJCiuleanuT, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med2005; 353: 123–132.
17.
ZhouCWuYLChenG, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011; 12: 735–742.
18.
RosellRCarcerenyEGervaisR, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol2012; 13: 239–246.
19.
LiDAmbrogioLShimamuraT, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene2008; 27: 4702–4711.
20.
SequistLVYangJCYamamotoN, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol2013; 31: 3327–3334.
21.
WuYLZhouCHuCP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol2014; 15: 213–222.
22.
EngelmanJAZejnullahuKGaleCM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res2007; 67: 11924–11932.
23.
EllisPMShepherdFAMillwardM, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol2014; 15: 1379–1388.
24.
RamalingamSSJannePAMokT, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol2014; 15: 1369–1378.
25.
WuYLChengYZhouX, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol2017; 18: 1454–1466.
26.
YuHAArcilaMERekhtmanN, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res2013; 19: 2240–2247.
27.
CrossDAAshtonSEGhiorghiuS, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Disc2014; 4: 1046–1061.
28.
YangJCAhnMJKimDW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol2017; 35: 1288–1296.
29.
GossGTsaiCMShepherdFA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol2016; 17: 1643–1652.
30.
MokTSWuYLAhnMJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med2017; 376: 629–640.
31.
AkamatsuHKatakamiNOkamotoI, et al. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci2018; 109: 1930–1938.
32.
KitagawaCMoriMIchikiM, et al. Gefitinib plus bevacizumab vs. gefitinib alone for EGFR mutant non-squamous non-small cell lung cancer. In Vivo2019; 33: 477–482.
33.
YoshidaKYamadaY.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. Transl Lung Cancer Res2015; 4: 217–219.
34.
SaitoHFukuharaTFuruyaN, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol2019; 20: 625–635.
35.
NakagawaKGaronEBSetoT, et al. RELAY: a multinational, double-blind, randomized phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol2019; 37 (15 suppl): 9000.
36.
UchinoJNakaoATamiyaN, et al. Treatment rationale and design of the SPIRAL study: a phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. Medicine2018; 97: e11081.
37.
AkamatsuHKohYOzawaY, et al. Osimertinib with ramucirumab in EGFR-mutated, T790M-positive patients with progression during EGFR-TKI therapy: phase Ib study. Clin Lung Cancer2018; 19: e871–e874.
38.
NakamuraAInoueAMoritaS, et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). J Clin Oncol2018; 36 (15 suppl): 9005.
39.
NoronhaVPatilVMJoshiA, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol2019: Jco1901154.
40.
UrataYKatakamiNMoritaS, et al. Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol2016; 34: 3248–3257.
41.
ParkKTanEHO'ByrneK, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol2016; 17: 577–589.
42.
Paz-AresLTanEHO'ByrneK, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol2017; 28: 270–277.
43.
SoriaJCOheYVansteenkisteJ, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med2018; 378: 113–125.
44.
SchremserKRogowskiWHAdler-ReichelS, et al. Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. PharmacoEconomics2015; 33: 1215–1228.
45.
GiulianiJRemoABonettiA.The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. Exp Rev Pharmacoecon Outcomes Res2017; 17: 5–8.
46.
WuBGuXZhangQ.Cost-effectiveness of osimertinib for EGFR mutation-positive non-small cell lung cancer after progression following first-line EGFR TKI therapy. J Thorac Oncol2018; 13: 184–193.
